Cel Sci Corp CVM
We take great care to ensure that the data presented and summarized in this overview for CEL SCI CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CVM
View all-
Vanguard Group Inc Valley Forge, PA2.37MShares$995,6460.0% of portfolio
-
Black Rock Inc. New York, NY775KShares$325,3750.0% of portfolio
-
Sabby Management, LLC Upper Saddle River, NJ712KShares$298,9282.94% of portfolio
-
Geode Capital Management, LLC Boston, MA572KShares$240,4430.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ432KShares$181,4930.0% of portfolio
-
State Street Corp Boston, MA215KShares$90,3860.0% of portfolio
-
Thoroughbred Financial Services, LLC192KShares$80,4970.0% of portfolio
-
Mai Capital Management160KShares$67,0320.0% of portfolio
-
Northern Trust Corp Chicago, IL118KShares$49,6910.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX114KShares$48,0060.0% of portfolio
Latest Institutional Activity in CVM
Top Purchases
Top Sells
About CVM
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Insider Transactions at CVM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2024
|
Geert R Kersten CEO |
BUY
Grant, award, or other acquisition
|
Direct |
12,940
+1.05%
|
$0
$0.4 P/Share
|
|
Dec 31
2024
|
Eyal Talor Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,001
+4.6%
|
$0
$0.4 P/Share
|
|
Dec 31
2024
|
Patricia B Prichep Chief Financial & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
10,727
+4.1%
|
$0
$0.4 P/Share
|
|
Sep 30
2024
|
Eyal Talor Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,264
+1.87%
|
$2,264
$1.06 P/Share
|
|
Sep 30
2024
|
Patricia B Prichep Chief Financial & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
4,047
+1.66%
|
$4,047
$1.06 P/Share
|
|
Sep 30
2024
|
Geert R Kersten CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,882
+0.4%
|
$4,882
$1.06 P/Share
|
|
Jun 28
2024
|
Eyal Talor Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,068
+1.75%
|
$2,068
$1.16 P/Share
|
|
Jun 28
2024
|
Geert R Kersten CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,461
+0.37%
|
$4,461
$1.16 P/Share
|
|
Jun 28
2024
|
Patricia B Prichep Chief Financial & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
3,698
+1.54%
|
$3,698
$1.16 P/Share
|
|
May 08
2024
|
Robert Eugene Watson Director |
BUY
Open market or private purchase
|
Direct |
20,000
+45.01%
|
$20,000
$1.39 P/Share
|
|
May 08
2024
|
Patricia B Prichep Chief Financial & Operations |
BUY
Open market or private purchase
|
Direct |
8,000
+3.33%
|
$8,000
$1.39 P/Share
|
|
May 08
2024
|
Geert R Kersten CEO |
BUY
Open market or private purchase
|
Direct |
30,000
+2.45%
|
$30,000
$1.39 P/Share
|
|
Mar 29
2024
|
Patricia B Prichep Chief Financial & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
2,246
+0.99%
|
$2,246
$1.91 P/Share
|
|
Mar 29
2024
|
Eyal Talor Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,256
+1.09%
|
$1,256
$1.91 P/Share
|
|
Mar 29
2024
|
Geert R Kersten CEO |
BUY
Grant, award, or other acquisition
|
Direct |
2,709
+0.23%
|
$2,709
$1.91 P/Share
|
|
Dec 29
2023
|
Eyal Talor Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
882
+0.77%
|
$1,764
$2.72 P/Share
|
|
Dec 29
2023
|
Geert R Kersten CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,819
+0.16%
|
$3,638
$2.72 P/Share
|
|
Dec 29
2023
|
Patricia B Prichep Chief Financial & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
1,577
+0.71%
|
$3,154
$2.72 P/Share
|
|
Sep 29
2023
|
Patricia B Prichep Chief Financial & Operations |
BUY
Grant, award, or other acquisition
|
Direct |
3,432
+1.53%
|
$3,432
$1.25 P/Share
|
|
Sep 29
2023
|
Eyal Talor Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,920
+1.68%
|
$1,920
$1.25 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 57.3K shares |
|---|---|
| Open market or private purchase | 58K shares |